“Chronic kidney disease is a global healthcare problem ... GLP-1 agonists – LEADER with liraglutide and SUSTAIN-6 with semaglutide – in which we included important renal endpoints.

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

The ‘4S’ Pathway was designed to guide shifting needs in older adults with diabetes who are struggling with diabetes ...

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial. The Danish ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industryLexaria's technology could enhance performance and lower side effects KELOWNA, BC / ACCESS Newswire / April 23, 20 ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Ozempic (semaglutide) and Wegovy (semaglutide ... kidney disease progression in adults with type 2 diabetes and chronic kidney disease — You should only take Ozempic or Wegovy for the ...

Board Certified in Endocrinology, Diabetes, and Metabolism and Internal Medicine, Dr. Caveney leads IQVIA’s Obesity, ...

Invokanna (also known as canagliflozin) is a third SGLT2 inhibitor that is FDA-approved to treat chronic kidney disease. And now the GLP1-receptor agonists, weight-loss drugs like Wegovy and Ozempic ...

The international community has a golden opportunity to start reining in the escalating, mostly ignored global burden of ...

Authors call for prospective studies to assess relationship with different indicators of kidney function. (HealthDay News) — Individuals who eat a proinflammatory diet have a higher likelihood ...